Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug

PR Newswire - Wed Sep 14, 2022

Collaboration combines leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN's long-standing experience in companion diagnostic development

Read more at prnewswire.com

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).